QLGN - Qualigen Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Carlsbad,
United States
Type: Equity
QLGN price evolution
QLGN
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $0.39 | $0.12 | $0.09 | $0.4 |
| Short term investments | ||||
| Net receivables | $1.3 | |||
| Inventory | ||||
| Total current assets | $2.31 | $0.53 | $1 | $1.17 |
| Long term investments | ||||
| Property, plant & equipment | ||||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $0.87 | |||
| Total investments | ||||
| Total assets | $2.31 | $0.53 | $1 | $2.03 |
| Current liabilities | ||||
| Accounts payable | $1.64 | $1.85 | $1.8 | $2.22 |
| Deferred revenue | ||||
| Short long term debt | $1.67 | $1.02 | $1.3 | |
| Total current liabilities | $4.45 | $4.81 | $4.52 | $4.14 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | $1.67 | $1.02 | $1.3 | |
| Total liabilities | $4.45 | $4.81 | $4.52 | $4.14 |
| Shareholders' equity | ||||
| Retained earnings | -$122.21 | -$120.41 | -$118.84 | -$116.8 |
| Other shareholder equity | ||||
| Total shareholder equity | -$4.28 | -$3.52 | -$2.1 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $0.4 | $7.04 | $17.54 | |
| Short term investments | ||||
| Net receivables | $0.54 | $0.82 | ||
| Inventory | $1.59 | $1.06 | $0.95 | |
| Total current assets | $1.17 | $10.82 | $20.8 | $6.13 |
| Long term investments | ||||
| Property, plant & equipment | $1.77 | $1.85 | $0.08 | |
| Goodwill & intangible assets | $6.47 | $0.17 | ||
| Total noncurrent assets | $0.87 | $8.26 | $2.04 | |
| Total investments | ||||
| Total assets | $2.03 | $19.08 | $22.84 | $6.69 |
| Current liabilities | ||||
| Accounts payable | $2.22 | $0.86 | $0.89 | $1.29 |
| Deferred revenue | $0.17 | $0.23 | ||
| Short long term debt | $1.3 | $1.25 | $0.13 | |
| Total current liabilities | $4.14 | $8.61 | $4.64 | $1.67 |
| Long term debt | $1.3 | $1.54 | ||
| Total noncurrent liabilities | $1.71 | $1.64 | ||
| Total debt | $1.3 | $2.55 | $1.68 | |
| Total liabilities | $4.14 | $10.32 | $6.27 | $1.67 |
| Shareholders' equity | ||||
| Retained earnings | -$116.8 | -$103.39 | -$84.74 | -$82 |
| Other shareholder equity | $0.05 | |||
| Total shareholder equity | -$2.1 | $7.24 | $16.56 | |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $0.75 | $0.36 | $1.31 | |
| Selling, general & administrative | $0.99 | $1.06 | $0.96 | |
| Total operating expenses | $1.27 | $1.74 | $1.42 | $2.27 |
| Operating income | -$1.74 | -$1.42 | -$2.27 | |
| Income from continuing operations | ||||
| EBIT | -$1.31 | -$1.89 | -$2.22 | |
| Income tax expense | -$0 | -$0 | $0 | -$0 |
| Interest expense | -$0.36 | $0.26 | $0.14 | $0.24 |
| Net income | ||||
| Net income | -$1.82 | -$1.58 | -$2.03 | -$2.45 |
| Income (for common shares) | -$1.58 | -$2.09 | -$2.45 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Jan 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $4.98 | $5.65 | $2.85 | |
| Cost of revenue | $4.3 | $4.33 | ||
| Gross Profit | $0.68 | $1.32 | $0.21 | |
| Operating activities | ||||
| Research & development | $5.21 | $6.84 | $11.72 | |
| Selling, general & administrative | $6.1 | $11.79 | $12.27 | |
| Total operating expenses | $11.3 | $22.86 | $23.98 | $10.73 |
| Operating income | -$11.3 | -$22.18 | -$22.66 | |
| Income from continuing operations | ||||
| EBIT | -$11.9 | -$18.88 | -$17.93 | |
| Income tax expense | -$0 | -$0.27 | $0.01 | |
| Interest expense | $1.52 | $0.03 | -$0.04 | -$0.05 |
| Net income | ||||
| Net income | -$13.42 | -$18.64 | -$17.9 | -$19.55 |
| Income (for common shares) | -$13.42 | -$18.64 | -$17.9 | |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$1.58 | -$2.03 | -$2.45 | |
| Operating activities | ||||
| Depreciation | $0 | |||
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.03 | $0.06 | $0.07 | |
| Total cash flows from operations | -$1.47 | -$0.78 | -$5.67 | |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$0.9 | $0.35 | $0.24 | |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.15 | |||
| Net borrowings | $1 | $0.47 | -$0.11 | |
| Total cash flows from financing | $4.94 | $1.15 | $0.47 | -$0.11 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$0.01 | $0.03 | -$0.31 | -$5.55 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Jan 2021 |
|---|---|---|---|---|
| Net income | -$13.42 | -$18.64 | -$17.9 | |
| Operating activities | ||||
| Depreciation | $0 | $0.38 | $0.34 | |
| Business acquisitions & disposals | $0.14 | |||
| Stock-based compensation | $1.1 | $5.48 | $5.29 | |
| Total cash flows from operations | -$10.3 | -$13.25 | -$14.73 | |
| Investing activities | ||||
| Capital expenditures | -$0.32 | -$0.13 | ||
| Investments | ||||
| Total cash flows from investing | $4.22 | -$0.18 | -$0.14 | -$0.07 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$0 | $8.82 | ||
| Net borrowings | -$0.55 | $2.9 | -$0.14 | |
| Total cash flows from financing | -$0.55 | $2.91 | $8.43 | $34.05 |
| Effect of exchange rate | $0.02 | |||
| Change in cash and equivalents | -$6.64 | -$10.52 | -$6.44 | $23.82 |
News
Fundamentals
| Market cap | $2.35M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 548.28K |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$7.88M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -0.30 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | 0.71 |
| EPS | -$14.37 |
|---|---|
| ROA | -535.78% |
| ROE | N/A |
| Debt/Equity | -1.97 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 0.52 |
| Quick ratio | N/A |